The invention concerns a novel cardiac therapeutic effective against atrial fibrillation (AF); a pharmaceutical composition comprising same; the use of same to treat cardiac disease; and a method of treating cardiac disease involving the use of same.
作者:Kaitlyn Corazzata、Peter J. Rose、Shunyan Mo、Joseph Snodgrass、Alexander Langston、Elaine C. Lee
DOI:10.1021/acs.oprd.1c00335
日期:2022.3.18
presence of alkylsulfonates, which were identified as potential genotoxic impurities in our active pharmaceutical ingredient (API). As a result, we initiated a development effort to identify a method to remove the alkylsulfonates that would be amenable for scale-up. Herein, we report our effort toward the development of a general approach using DABCO (1,4-diazabicyclo[2.2.2]octane) to remove alkyl sulfonates
Isocyanatoalkylsulfonate und ein Verfahren zu deren Herstellung
申请人:BAYER AG
公开号:EP0433806A2
公开(公告)日:1991-06-26
Isocyanatoalkylsulfonate der allgemeinen Formel
mit den in der Beschreibung angegebenen Substituentenbedeutungen erhält man durch Umsetzung der entsprechenden Isocyanatoalkylhalogenide mit Sulfonsäureestern der Formel
worin R³ die in der Beschreibung angegebenen Bedeutungen besitzt. Sie finden Verwendung als Vernetzer in Polyaminen.
Polymerizable composition for polythiourethane optical material, polythiourethane optical material obtained from the polymerizable composition, and polymerization catalyst for polythiourethane optical material
申请人:Mitsui Chemicals, Inc.
公开号:EP2407498A2
公开(公告)日:2012-01-18
The polymerizable composition for a polythiourethane optical material of the present invention includes (A) a polymerization catalyst for a polythiourethane optical material, (B) at least one compound selected from an isocyanate compound and an isothiocyanate compound, and (C) a compound containing one or more mercapto groups, wherein said polymerization catalyst for a polythiourethane optical material (A) includes (a1) a zinc compound, and (a4)a compound represented by the following general formula (4).
To provide an industrial method for producing a cationic lipid, which does not require a special equipment and by which a cationic lipid of high purity can be efficiently obtained. A cationic lipid represented by formula (1) is mixed with a tetraalkylammonium salt having X- in an organic solvent, and a filtrate obtained by separating a tetraalkylammonium iodide deposited by filtration is concentrated to deposit a tetraalkylammonium iodide, thereby obtaining a cationic lipid represented by formula (2):